Research programme: polycefin therapeutics - Arrogene

Drug Profile

Research programme: polycefin therapeutics - Arrogene

Alternative Names: AG-101; AG-102; AG-103

Latest Information Update: 20 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arrogene
  • Class Antisense oligonucleotides; Biopolymers
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor inhibitors; Laminin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain cancer; Breast cancer; Lung cancer

Most Recent Events

  • 25 Apr 2016 Preclinical trials in Lung cancer in USA (IV) before April 2016 (Arrogene 10-K, April 2016)
  • 25 Apr 2016 Arrogene plans to file an IND application with the US FDA for Brain tumours (Arrogene 10-K, April 2016)
  • 25 Apr 2016 Arrogene plans a phase I trial for Brain tumours in USA (Arrogene 10-K, April 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top